Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
  1. Home
  2. Search

Refine search

Refine search

Access:
Content type:
Publication date:
Apply   From and To filters
Subject: Show more
Journals Show more
Publishers: Show more
Societies Show more
Series: Show more
Collections: Show more

Actions for selected content:

Select all | Deselect all
  • View selected items
  • Export citations
  • Download PDF (zip)
  • Save to Kindle
  • Save to Dropbox
  • Save to Google Drive

Save Search

You can save your searches here and later view and run them again in "My saved searches".

Please provide a title, maximum of 40 characters.
Cancel
×

1 results

  • 17 - Apolipoprotein E as a marker in the treatment of Alzheimer's disease

  • from Part V - Specific psychotropic drugs and disorders
  • Edited by Bernard Lerer, Hadassah-Hebrew Medical Center, Jerusalem
  • Book:
    Pharmacogenetics of Psychotropic Drugs
    Published online:
    20 August 2009
    Print publication:
    29 August 2002, pp 360-371

  • Summary

    This chapter focuses specifically on the pharmacogenetic role of the risk factor gene apolipoprotein E (ApoE) in Alzheimer's disease (AD) and in the response of patients with AD to treatment. ApoE has been extensively studied in non-nervous tissues as one of several proteins that regulate lipid transport and metabolism. ApoE facilitates cholesterol (and phospholipid) transport between different cell types and different organs. It binds to large lipid-protein particles (called lipoproteins). The chapter divides AD drug therapy into two broad categories, the cholinergic and noncholinergic drugs. One of the goals of pharmacogenetics is to deliver the right medicine to the right patient. The retrospective studies presented here show that the pharmacogenetic impact of the apoE alleles are a step in this direction as there are definitely drugs that work better in non-apoE4 carriers (for example, tacrine) and those that work better in the apoE4 carriers (for example, S12024).